[go: up one dir, main page]

WO2008040995A8 - Indazoles for use as dpp-iv inhibitors - Google Patents

Indazoles for use as dpp-iv inhibitors

Info

Publication number
WO2008040995A8
WO2008040995A8 PCT/GB2007/003788 GB2007003788W WO2008040995A8 WO 2008040995 A8 WO2008040995 A8 WO 2008040995A8 GB 2007003788 W GB2007003788 W GB 2007003788W WO 2008040995 A8 WO2008040995 A8 WO 2008040995A8
Authority
WO
WIPO (PCT)
Prior art keywords
dpp
inhibitors
indazoles
relates
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2007/003788
Other languages
French (fr)
Other versions
WO2008040995A1 (en
WO2008040995A9 (en
Inventor
Adrian Maddaford
Rebecca Glen
David Paul Leese
Terance William Hart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Concept Life Sciences Ltd
Original Assignee
Peakdale Molecular Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0619906A external-priority patent/GB0619906D0/en
Priority claimed from GB0624719A external-priority patent/GB0624719D0/en
Application filed by Peakdale Molecular Ltd filed Critical Peakdale Molecular Ltd
Publication of WO2008040995A1 publication Critical patent/WO2008040995A1/en
Publication of WO2008040995A8 publication Critical patent/WO2008040995A8/en
Publication of WO2008040995A9 publication Critical patent/WO2008040995A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to indazole derivatives useful as dipeptidyl peptidase IV (DPP-IV) inhibitors.
PCT/GB2007/003788 2006-10-07 2007-10-04 Indazoles for use as dpp-iv inhibitors Ceased WO2008040995A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0619906.1 2006-10-07
GB0619906A GB0619906D0 (en) 2006-10-07 2006-10-07 Compounds
GB0624719.1 2006-12-12
GB0624719A GB0624719D0 (en) 2006-12-12 2006-12-12 Compounds

Publications (3)

Publication Number Publication Date
WO2008040995A1 WO2008040995A1 (en) 2008-04-10
WO2008040995A8 true WO2008040995A8 (en) 2008-10-23
WO2008040995A9 WO2008040995A9 (en) 2008-12-31

Family

ID=38894055

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2007/003788 Ceased WO2008040995A1 (en) 2006-10-07 2007-10-04 Indazoles for use as dpp-iv inhibitors
PCT/GB2007/003758 Ceased WO2008040974A1 (en) 2006-10-07 2007-10-04 Indoles for use as dpp-iv inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/003758 Ceased WO2008040974A1 (en) 2006-10-07 2007-10-04 Indoles for use as dpp-iv inhibitors

Country Status (1)

Country Link
WO (2) WO2008040995A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
EP2392575A1 (en) 2010-06-04 2011-12-07 LEK Pharmaceuticals d.d. A novel synthetic approach to ß-aminobutyryl substituted compounds
WO2011151443A1 (en) 2010-06-04 2011-12-08 Lek Pharmaceuticals D.D. A NOVEL SYNTHETIC APPROACH TO ß-AMINOBUTYRYL SUBSTITUTED COMPOUNDS
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN102627648B (en) * 2012-04-14 2014-11-12 江苏施美康药业股份有限公司 Preparation method of sitagliptin
IN2015DN03795A (en) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
CN104987338B (en) * 2015-07-30 2017-07-21 新发药业有限公司 A kind of preparation method of Sitagliptin phosphate key intermediate
CN106668056B (en) * 2016-11-08 2019-12-10 中国人民解放军第二军医大学 Combination of adenosine and nNOS inhibitors for preventing central nervous system oxygen poisoning
WO2023060362A1 (en) * 2021-10-15 2023-04-20 Genetolead Inc. Ras inhibitors, compositions and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005265148B2 (en) * 2004-06-21 2011-01-20 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes

Also Published As

Publication number Publication date
WO2008040995A1 (en) 2008-04-10
WO2008040995A9 (en) 2008-12-31
WO2008040974A1 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
WO2008040995A8 (en) Indazoles for use as dpp-iv inhibitors
HUS2000049I1 (en) Substituted indazole derivatives active as kinase inhibitors
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
EP2133077A4 (en) Derivatives of azabicyclo octane, the method of making them and the uses thereof as inhibitors of dipeptidyl peptidase iv
GB201004478D0 (en) Novel compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
HUS1400009I1 (en) Administration of dipeptidyl peptidase inhibitors
MX2008001799A (en) Pharmaceutical composition comprising a dpp-iv inhibitor.
IL177629A0 (en) Dipeptidyl peptidase inhibitors
IL190131A0 (en) Dipeptidyl peptidase inhibitors for treating diabetes
EP2057158B8 (en) Triazole derivatives as kinase inhibitors
ZA200801007B (en) Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
WO2007143434A3 (en) Indazole and isoindole derivatives as glucokinase activating agents
WO2005030751A3 (en) Dipeptidyl peptidase inhibitors
PT2120932E (en) Indazole derivatives as kinase inhibitors for the treatment of cancer
EP2001480A4 (en) Indazole compounds
IL202318A0 (en) 5-heteroaryl substituted indazoles as kinase inhibitors
AU2003207881A1 (en) Dipeptidyl peptidase inhibitors
AP2321A (en) Quinoline derivatives for use as mycobactrial inhibitor.
WO2009111239A3 (en) Pyrrolidine derivatives
IL200653A0 (en) Weekly administration of dipeptidyl peptidase inhibitors
AP2010005345A0 (en) Indazole derivatives.
SI2049480T1 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-1 INHIBITORS
PL2148876T3 (en) Pyrazolone derivatives as pde4 inhibitors
WO2010107809A3 (en) Methods for preparing dpp-iv inhibitor compounds
ZA200808598B (en) Pyrrolopyrimidine derivatives used as HSP90 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07824042

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07824042

Country of ref document: EP

Kind code of ref document: A1